ClinVar Miner

Submissions for variant NM_002834.5(PTPN11):c.227A>G (p.Glu76Gly)

dbSNP: rs121918465
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000014266 SCV000204032 pathogenic Juvenile myelomonocytic leukemia 2015-10-18 criteria provided, single submitter clinical testing The p.Glu76Gly variant in PTPN11 has been reported as a somatic change in >10 in dividuals with juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia ( AML), or childhood acute lymphoblastic leukemia (ALL; Tartaglia 2003, Tartaglia 2004, Loh 2004, Kratz 2005). In addition, many other variants at this position h ave been frequently identified as a somatic change in individuals with JMML, AML , and ALL, and codon 76 in PTPN11 has been described as the mutational hot-spot for JMML (Tartaglia 2003). It was absent from large population studies. In summa ry, this variant meets our criteria to be classified as pathogenic for JMML.
GeneDx RCV000159046 SCV000208988 pathogenic not provided 2018-01-22 criteria provided, single submitter clinical testing The E76G pathogenic variant in the PTPN11 gene lies within the region coding for the N-SH2 domain, which is a hot spot for mutations in Noonan syndrome (Tartaglia et al., 2001 and Tartaglia et al., 2006). The E76G is not observed in large population cohorts (Lek et al., 2016). It is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties, and in-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Another amino acid substitution at codon 76, E76D, has been reported as germline pathogenic variant in approximately 3% of individuals with Noonan syndrome (Kratz et al., 2005). Other missense variants at the same codon have also been reported as somatic variants in association with juvenile myelomonocytic leukemia (JMML) and other hematologic malignancies (Shimada et al., 2004 and Tartaglia et al., 2006). It has been hypothesized that residues with strong associations to isolated JMML, like this variant, often result in embryonic lethal or severe clinical presentations if inherited as a germline variant (Mason-Suares et al., 2017, Tartaglia et al., 2006; Lee KA et al., 2009, Chan RJ, et al., 2007 Tartaglia M, et al., 2003).
Invitae RCV002513040 SCV003442104 uncertain significance RASopathy 2023-12-14 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 76 of the PTPN11 protein (p.Glu76Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with somatic juvenile myelomonocytic leukemia and a fetus with a heart defect, hydrops, and persistent cystic hygroma (PMID: 12717436, 14644997, 21901340, 23756559, 23832011, 28098151). ClinVar contains an entry for this variant (Variation ID: 13338). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PTPN11 protein function with a positive predictive value of 95%. This variant disrupts the p.Glu76 amino acid residue in PTPN11. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 11704759, 12634870, 16830086, 18678287, 22190897). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002513040 SCV003934850 likely pathogenic RASopathy 2023-05-22 criteria provided, single submitter clinical testing Variant summary: PTPN11 c.227A>G (p.Glu76Gly) results in a non-conservative amino acid change located in the SH2 domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251068 control chromosomes. c.227A>G has been reported in the literature in individuals affected with Noonan Syndrome or Juvenile myelomonocytic leukemia (examples: Unal_2010, Timeus_2013, Mason-Suares_2017). At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity (examples: Ren_2007, Niihori_2005, Lee_2008, Tien_2016). The following publications have been ascertained in the context of this evaluation (PMID: 23756559, 19798502, 36349709, 28098151, 17942397, 15834506, 18559669, 26783207, 19179468). Two ClinVar submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, classifying the variant as pathogenic and uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic.
OMIM RCV000014266 SCV000034515 pathogenic Juvenile myelomonocytic leukemia 2003-06-01 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000437931 SCV000507254 likely pathogenic Multiple myeloma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000420699 SCV000507255 likely pathogenic Astrocytoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000427060 SCV000507256 likely pathogenic Squamous cell lung carcinoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000437713 SCV000507257 likely pathogenic Neuroblastoma 2016-05-31 no assertion criteria provided literature only
Database of Curated Mutations (DoCM) RCV000419574 SCV000507258 likely pathogenic Neoplasm of the large intestine 2016-05-31 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.